Matthews Asia's Sean Taylor explains why he remains constructive on China despite the broader indexes lagging some high-performing sectors. He also outlines his South Korea strategy, including an ...

How to make big, well, some bucks in late night? According to CBS, the trick is to cancel your traditional show and lease the time to someone else. The Paramount Skydance broadcast outlet, which has ...

Generate:Biomedicines (NASDAQ: GENB), the drug developer focused on creating immunology and inflammation (I&I) and oncology treatments through its own artificial intelligence (AI)-based platform, has ...

Blake has over a decade of experience writing for the web, with a focus on mobile phones, where he covered the smartphone boom of the 2010s and the broader tech scene. When he's not in front of a ...

To use the Sentinel-Authenticator, you need to provide a configuration in a txt file where each line represent a otpauth url in the format of otpauth://TYPE/LABEL ...

Ready your sides for a relentless laugh riot as we dive into some of the most iconic Monty Python one-liners ever written! From absurd insults to absurdist wit, these zingers perfectly showcase the ...

An ongoing and heated dispute between the Pentagon and Anthropic is raising new questions about how the startup’s technology is actually used inside the US military. In late February, Anthropic ...

Use left and right arrow keys to seek audio. Microsoft's Jason Ronald reveals new details about the next-gen Project Helix console at GDC 2026, as per a recent live stream. Microsoft confirming key ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate:Biomedicines has earmarked $300 million of its IPO funds to complete a pair of phase 3 asthma trials for its anti-TSLP antibody GB-0895. (Fabrice Cabaud/Stock/Getty Images Plus) ...